Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
With approximately 50 percent of its overall early-to-mid-stage pipeline emerging from collaborations, the company』s research strategy is firmly anchored in external innovation for all therapeutic ......
